PROVIDENCE, R.I. (AP) — Rhode Island may not be able to meet President Joe Biden’s goal of making all adults eligible for a COVID-19 vaccine by May because of a limited supply, state health officials said Tuesday.

Much depends on the state’s allocation of Johnson & Johnson’s single-dose shot, officials said at a meeting of the state’s COVID-19 Vaccine Subcommittee, WPRI-TV reported.

The state received 1,300 doses of the J&J vaccine this week, following an initial shipment of 9,100 doses at the beginning of March, but officials projected the state would receive 16,000 doses per week in the near future.

The state on Tuesday made just 1,890 new first-dose appointments available, because most of the doses this week are being used for second shots, health officials said. About 10,000 first dose slots are opening this week at the retail pharmacy locations, according to Joseph Wendelken, a spokesperson for the Health Department.

The state this week will also be updating its signup website, vaccinateRI.org, to reduce error messages and to set up a virtual “waiting room” to take care of the issue of appointments appearing to be available, even though other people are in the process of booking them.

___

SALIVA TEST

Researchers at the University of Rhode Island have developed a saliva-based COVID-19 test that they say is less invasive than the more common nasal swab tests and less expensive.

The test is currently undergoing clinical trials on campus as part of the final phase of data collection and validation in preparation for submission to the U.S. Food and Drug Administration for emergency use authorization.

According to the university, FDA approval would have “far-reaching implications, both at home and abroad, in terms of increasing accessibility to testing to help manage pandemic response.”